A Democratic bill with no cosponsors
Last activity — Referred to the House Committee on Energy and Commerce.
In committee
Introduced and handed to a committee in the chamber it started in.
The committee holds it, and most bills are never heard from again. A hearing or a committee vote would be news; silence is the usual outcome, and it kills the bill without anyone voting against it.
Its path through Congress
- Introduced
- In Committee
What this bill would do
This bill, known as the "Hormone Health Data and Research Act," directs specific federal actions regarding perimenopause. The Director of the National Institutes of Health is tasked with evaluating evidence regarding hormone level variability and baseline patterns in women before they experience perimenopause symptoms. Additionally, the Secretary of Health and Human Services, through the U.S. Preventive Services Task Force, must review evidence on the clinical utility of hormone testing. The goal is to determine if baseline hormone information helps in the diagnosis or management of perimenopause. Both entities are required to submit a report summarizing their findings and recommendations within 18 months.
Yes· 3 of 5
- Scored +4
Would women be better off under this?
The bill seeks to improve the diagnosis and management of perimenopause through specialized clinical research.
- Scored +3
Would people in middle age be better off under this?
The bill focuses on medical research for perimenopause, a health transition typically occurring in middle age.
- Scored +3
Does this make health care easier to get in general?
The bill directs studies that may lead to better clinical guidance and management of perimenopause.
The opposite
No question was scored the opposite.
Who it would affect, and how
Potential Positive Impacts for People
-
Improved understanding of hormonal changes: The NIH will evaluate evidence regarding how hormone levels vary and what baseline patterns exist before perimenopause symptoms begin (Section 2(a)). This could lead to better knowledge of how women's bodies change.
-
Better clinical management and diagnosis: The U.S. Preventive Services Task Force will review if hormone testing and baseline information can meaningfully inform the diagnosis or management of perimenopause (Section 2(b)). This could lead to clearer medical guidance for women experiencing these transitions.
-
Identification of future research needs: The required report will summarize findings and identify evidence gaps (Section 2(c)). This helps ensure that future research and clinical guidance are directed toward the most important areas for women's health.
Potential Negative Impacts for People
- No specific negative impacts are identified in the provided text.
Groups and Interests Ranking
Every group the model scored this bill for, from -10 to +10. Tap or hover a score for the reason it gave.
- Demographic And Interest Groups
- Would women be better off under this? — The bill seeks to improve the diagnosis and management of perimenopause through specialized clinical research. Would people in middle age be better off under this? — The bill focuses on medical research for perimenopause, a health transition typically occurring in middle age.
- Healthcare
- Does this make health care easier to get in general? — The bill directs studies that may lead to better clinical guidance and management of perimenopause. Does this put more money into medical research? — The bill mandates specific research evaluations by the NIH regarding hormone variability.
- Social Issues And Justice
- Does this narrow the gap between how men and women are treated? — The bill focuses on addressing health knowledge gaps specific to women's hormonal health during perimenopause.
- 5/29/2026
- Referred to the House Committee on Energy and Commerce.
- Introduced in House